235

SUDDEN INFANT DEATH SYNDROME (SIDS) AMONG INFANTS OF DRUG DEPENDENT MOTHERS (IDDM). Cleofe J. Chavez, Joan C. Stryker, Enrique M. Ostrea, Jr., Depts. of Peds.,

Obstet./Gynec., Wayne State Univ. & Hutzel Hospital, Detroit, MI

Sudden unexpected death among IDDM is a major medical problem. Our experience at Hutzel Hospital shows a very high incidence of SIDS among the IDDM (17/1000). A retrospective study of IDDM was performed to determine if any neonatal factors exist which may predispose to sudden unexpected infant death.

RESULTS: From 9/74 to 9/77 a total of 637 fullterm IDDM weighing at least 2268 g were delivered. Using the criteria previously reported, the severity of neonatal drug withdrawal was assessed: 89% (564/637) had minor to mild (MM) and 12% (73/637) moderate to severe (MS) withdrawal. Two percent (14/637) were later reported to have died of SIDS. A significantly higher number of infants with MS (6/73) died of SIDS compared to those with MM withdrawal (8/564), $\chi^2=9.060$, $p<0.01$. Those who died had no significant medical problems during the neonatal period. All died between 4-16 weeks of age: 57% in Winter, 21% in Summer and 21% in the Fall.

CONCLUSION: 1) The frequency of SIDS is higher among IDDM compared to the general population. 2) A significantly higher incidence of infants with MS withdrawal died from SIDS compared to those who had lesser degrees of withdrawal. 3) Since there is a correlation between maternal methadone dose and severity of neonatal withdrawal (J Pediatr, April/76), the use of low methadone dosage during pregnancy is strongly recommended.

238

RESPONSES TO MORPHINE IN THE PREGNANT EWE Martin S. Cohen, Abraham M. Rudolph and Kenneth L. Melmon

University of California San Francisco, Departments of Pediatrics and Medicine, San Francisco.

It is not known whether the fetus can develop opiate dependence (OD) as a primary, drug-related effect of maternal to fetal transfer of morphine sulfate (MS) or whether fetal responses are related to altered maternal physiology. Four non-pregnant and 4 pregnant ewes were studied. A continuous intravenous (IV) infusion of MS was given to the ewes (10 mg/kg/24 hours). The response was measured to IV administration of naloxone (N), 0.04 mg/kg to the ewes and 0.02 mg/kg-estimated weight to the fetuses. As early as 24 hours after beginning the MS infusion, N increased arterial blood pressure (ABP) in the non-pregnant ewes (mean $\pm$ SE): systolic 120.2 ± 2.2 torr to 137.6 ± 2.4 ($p<.001$); diastolic 82.3 ± 1.2 to 95.9 ± 2.7 ($p<.001$); and in pregnant ewes: systolic 114.2 ± 2.6 to 140.7 ± 3.0 ($p<.001$). All animals demonstrated "withdrawal" responses. There was no significant change in heart rate. Maternal N increased fetal ABP: systolic 63.9 ± 2.1 to 75.0 ± 4.2 ($p<.001$); diastolic 36.8 ± 2.0 to 41.8 ± 2.7 ($p<.001$). In contrast to the mothers, there was a fall in fetal heart rate: 174 ± 6 to 150 ± 5 ($p<.001$) and pO_2 24.4 ± 0.81 to 22.2 ± 1.04 ($p<.05$) and meconium appeared in the amniotic fluid. N administered to the fetus produced similar significant changes plus arterial pH fell from 7.39 ± 0.01 to 7.35 ± 0.02 ($p<.05$). In a lamb born after 14 days of MS infusion to the ewe, N produced cardiovascular responses similar to those before birth, and the "withdrawal" responses seen in the ewes. MS, therefore, crosses the placenta and has a primary drug effect in the fetus. In addition, the fetus has a unique pharmacologic response to N after exposure to MS. This suggests the potential for development of OD in the fetus as a primary, drug-related effect of maternal to fetal transfer of MS.

236

PHARMACOKINETICS OF AMIKACIN IN CHILDREN WITH MALIGNANCIES. Thomas Cleary, Larry K. Pickering, Steven J. Culbert, William Kramer, Steve Kohl, Stuart Feldman, Jan van Eys (Spon. by R. Rodney Howell).

The Univ. of Tex. Med. School, Dept. Inf. Dis. & Pediatr., The Univ. of Tex. System Canc. Ctr., Dept. Pediatr., The Univ. of Houston, Dept. Pharm., Houston, Texas.

Amikacin is an aminoglycoside antibiotic that is effective against gram negative bacilli which are resistant to other aminoglycoside antibiotics. Pharmacokinetic data of amikacin in pediatric patients are scant. The pharmacokinetics of amikacin were evaluated in 30 hospitalized children (5 to 14 years of age) with malignancies. Children receiving 15 or 20 mg/kg/24 hr administered every 8 to 6 hours, respectively had peak serum concentrations of 16.9 ± 3.67 μ g/ml (mean $\pm$ SD) at the end of a one hour infusion. Six and 8 hour serum concentrations were 1.27 ± 1.26 and 0.64 ± 0.92 μ g/ml, respectively. The $t_{1/2}$ was 78 ± 43.8 minutes and the total clearance was 133 ± 43 ml/min/1.73 m^2 . The mean volume of distribution was 0.26 ± 0.08 l/kg. No accumulation of amikacin was noted and no side effects occurred. A 9% inactivation of amikacin occurred when incubated in normal donor sera at 37°C for 72 hours with varying concentrations of ticarcillin. Due to the rapid renal clearance and short half life of amikacin in these children, the currently recommended dose of amikacin should be increased and the frequency of administration shortened.

239

DECREASE IN α -ADRENERGIC BINDING SITES IN NEWBORN PLATELETS: CAUSE OF ABNORMAL RESPONSE TO EPINEPHRINE? Corby, D.G., Barber, J.A., and O'Barr, T.P. Clinical

Investigation Service, Fitzsimons Army Medical Center, Denver, Co. Platelets of newborn infants show diminished aggregation to epinephrine. Because epinephrine-induced aggregation is an α -adrenergic receptor-mediated response, we considered the possibility that platelets of newborn infants possess fewer epinephrine binding sites than do those of adults. Using the specific and potent α -adrenergic antagonist, [3 H] dihydroergocryptine (DHE), we compared the specific DHE binding to α -adrenergic binding sites in platelets from paired maternal and cord blood samples. Platelets were washed twice with buffer (Tris-HCl, 0.05 M, pH 7.35; NaCl, 0.15 M; EDTA, 0.02 M) and incubated with either 5 nM [3 H] DHE or 5 nM [3 H] DHE + 1 mM epinephrine. After 18 min, the reaction was stopped by adding excess buffer and the platelets were recovered by filtering on Whatman GFC glass fiber filters. Maternal platelets were found to bind approximately two-fold more [3 H] DHE than platelets from cord blood (2.06 vs. 1.11 femtomoles/ 10^7 platelets; $p<0.01$). Since maternal and cord blood platelets are the same size, it appears that newborn platelets have fewer binding sites for epinephrine than maternal platelets. The above data is consistent with the hypothesis that platelets from newborns have a) diminished aggregation response to epinephrine secondary to decreased numbers of receptors and b) α -adrenergic receptors that are either down regulated or not fully developed.

237

PLACENTAL TRANSFER OF MORPHINE IN THE EWE Martin S. Cohen, Abraham M. Rudolph and Kenneth L. Melmon

University of California San Francisco, Departments of Pediatrics and Medicine, San Francisco.

Maternal and fetal plasma clearance of morphine (M) as well as maternal to fetal and fetal to maternal clearance of M were studied in 4 chronically catheterized pregnant ewes and their fetuses. Morphine sulfate was infused into the ewes at a rate of 0.329 ± 0.06 mg/min for 4 hours. Arterial plasma M concentrations were measured by radioimmunoassay at specific intervals in the ewes and fetuses during and after the infusion. Twenty-four hours later, M was infused into the fetuses at a rate of 0.054 ± 0.013 mg/min for 4 hours and respective M concentrations measured. During the maternal infusion, the steady state plasma concentration of M achieved by the ewes was 97.8 ± 17.6 ng/ml and by the fetuses 14.7 ± 8.4 ng/ml. During the fetal infusion, the steady state plasma concentration of M achieved by the fetuses was 141.2 ± 63.4 ng/ml and by the ewes 3.5 ± 1.7 ng/ml. Plasma clearance of M in the ewes was 3369 ± 397 ml/min and in the fetuses was 425 ± 150 ml/min. The maternal to fetal clearance of M was 65.1 ± 40.4 ml/min. The fetal to maternal clearance of M was 84.4 ± 33.2 ml/min. These results indicate that only 20.0 $\pm$ 5.0 % of the total fetal clearance can be accounted for by fetal to maternal clearance. This suggests that maternal clearance of morphine is not the major route of elimination for the fetus. It cannot be assumed, however, that the remaining clearance is exclusively fetal metabolism since renal excretion of unchanged drug and placental metabolism were not determined.

240

INTRAVENOUS GENTAMICIN PHARMACOKINETICS IN THE SMALL PRETERM INFANT. William F. Coyer, George E. Wesbey, Katherine L. Cech, John A. Robinson, Loyola Univ.

Stritch Sch. of Med., Depts. of Peds. and Med., Maywood, IL (Spon. by John D. Madden)

Gentamicin (G) is an aminoglycoside frequently used in the treatment of neonatal sepsis and meningitis. This study reports for the first time the sequential pharmacokinetics of a constant rate one hour intravenous G infusion in 60 small preterm infants during the first week of use. Using a microbiologic technique, the serum G concentration (level) was measured before the 2.5 mg/kg G infusion and 1, 2, 4, 8, and 12 hours after the infusion was started. Mean birthweight and gestational age were 1365 grams (700-2000) and 30.5 weeks (24-36).

Potentially toxic trough and peak levels were observed in some cases along with a markedly prolonged half life ($t_{1/2}$). The peak, 2 hour (hr), and 12 hr (trough) levels were 8.25 ($1.7-13.0$), 5.76 ($.25-13.0$), and 2.03 ($.25-10.8$) μ g/ml respectively. Drug accumulation was documented. Increasing peak levels were associated with increased trough levels and decreased volume of distribution (V_D). Trough levels increased as dose and day of treatment increased and as V_D decreased. Drug disposition was very rapid during the first 4 hrs and slower during the last 8 hrs suggesting a two compartment process. $t_{1/2}$ was 12.36 hrs and V_D .802 l/kg (6.82 hrs and 0.629 l/kg respectively using a one compartment model). Biweekly monitoring of trough and peak levels is necessary to avoid peak levels >12 μ g/ml and trough levels >2 μ g/ml while maintaining therapeutic levels of 4-5 μ g/ml.